Elicio Therapeutics, Inc.
ELTXAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Mar 13, 2026 | H.C. Wainwright | Robert Burns | $17.00(+56%) | $10.90 | StreetInsider |
| Mar 9, 2026 | C.L. King | Michael King | $17.00(+44%) | $11.78 | TheFly |
| Jun 30, 2022 | Stifel Nicolaus | Annabel Samimy | $1.50(-12%) | $1.71 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| B. Riley Securities | maintain | Buy | Sep 24, 2026 |
| HC Wainwright & Co. | maintain | Buy | Aug 18, 2026 |
| Jones Trading | downgrade | Buy →Hold | Jun 16, 2026 |
| HC Wainwright & Co. | maintain | Buy | Jun 15, 2026 |
| HC Wainwright & Co. | maintain | Buy | May 28, 2026 |
| HC Wainwright & Co. | maintain | Buy | Mar 13, 2026 |
| HC Wainwright & Co. | maintain | Buy | Jul 17, 2025 |
| HC Wainwright & Co. | maintain | Buy | Apr 2, 2025 |
| HC Wainwright & Co. | maintain | Buy | Aug 23, 2024 |
| HC Wainwright & Co. | maintain | Buy | Jun 6, 2024 |
| HC Wainwright & Co. | maintain | Buy | May 22, 2024 |
| HC Wainwright & Co. | maintain | Buy | May 1, 2024 |
| Oppenheimer | maintain | Perform | Apr 1, 2024 |
| HC Wainwright & Co. | maintain | Buy | Jan 17, 2024 |
Earnings History
Next report: Mar 11, 2027 · EPS est. $-0.37| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Nov 5, 2026 | $-0.30 | $-0.44 | — | — |
| Aug 13, 2026 | $-0.43 | $-0.54 | — | — |
| May 11, 2026 | $-0.65 | $-0.49 | — | — |
| Mar 12, 2026 | $-0.49 | $-0.47 | — | — |
| Nov 13, 2025 | $-0.60 | $-0.62 | — | — |
| Aug 7, 2025 | $-0.66 | $-0.69 | — | — |
| May 13, 2025 | $-0.87 | $-0.67 | — | — |
| Mar 31, 2025 | $-1.02 | $-0.94 | — | — |
News
BOSTON, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today reported financial results for the quarter ended September 30, 2026, and provided recent corporate and clinical updates.
BOSTON, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that it will host a virtual key opinion leader (“KOL”) event on Wednesday, November 11, 2026, at 2:30 PM ET. To register, click here.
Keynote/plenary session and late-breaking poster presentation highlight additional data from Phase 2 AMPLIFY-7P trial of camupepimut (ELI-002 7P) in KRAS-mutated pancreatic cancer Additional preclinical poster presentation showcases an expanded application of the AMP-platform in an antigen-agnostic intratumoral treatment approach BOSTON, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-g…
BOSTON, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced results from the randomized Phase 2 AMPLIFY-7P study of camupepimut (ELI-002 7P), presented in a late-breaking Proffered Paper oral session at the European Society for Medical Oncology (“ESMO”) Congress 2026 in Madrid, Spain, and simultaneously published in Nature …
New pre-specified analyses from the randomized Phase 2 study will further characterize the clinical potential of ELI-002 7P (camupepimut) in adjuvant pancreatic cancer Findings are expected to inform a refined Phase 3 development strategy BOSTON, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that new pre-specified an…
BOSTON, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that Robert Connelly, Chief Executive Officer and Pete DeMuth, PhD, Chief Scientific Officer, will participate in a fireside chat at the upcoming H.C. Wainwright 28th Annual Global Investment Conference, taking place September 14-16, 2026, in New York, New York.
BOSTON, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that management will participate in one-on-one meetings at the upcoming Wells Fargo 21st Annual Healthcare Conference, taking place September 8-10, 2026, in Boston, MA.
Following the observation of multiple complete responses, Elicio plans to initiate a Phase 1 combination study of ELI-002 7P plus a RAS small molecule inhibitor with or without an anti-PD-1 inhibitor in metastatic pancreatic cancer; Phase 1 study anticipated to initiate Q4 2026